Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Shandong's Blue Sail Acquires New Valve Technology of Switzerland for $160 Million

publication date: Sep 25, 2019

Blue Sail Medical of Shandong and Biosensors, a subsidiary of Blue Sail, will pay $160 million to acquire New Valve Technology, a Swiss medical device company. NVT specializes in safe, cost-effective, minimally invasive heart valve replacements. Its Allegra transcatheter aortic valve replacement device was approved in the EU in 2017. Blue Sail is known primarily for its disposable medical/surgical PVC gloves, while its Biosensors subsidiary, located in Singapore, makes stents, a complementary market to NVT's products. More details....

Stock Symbol: (SHZ: 2382)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital